Updated monarchETrial data shows abemaciclib continues to benefit patients with high-risk, HR-positive, HER2-negative, early-stage breast cancer


Estimated Read Time:

1 minute

Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented during General Session 1 at SABCS 20 on Wednesday, Dec. 9

“While many patients with HR-positive early breast cancer will not experience recurrence on endocrine therapy alone, approximately 20 percent may experience disease recurrence in the first 10 years, often in the form of incurable metastatic breast cancer,” said Priya Rastogi, MD, Associate Professor at the University of Pittsburgh Department of Medicine and Medical Director of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation.

Click here to read the full AACR press release.